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Abstract: Curcumin is a polyphenol compound extracted from the rhizome of Curcuma longa Linn
(family Zingiberaceae) commonly used as a spice to color and flavor food. Several preclinical studies
have suggested beneficial roles for curcumin as an adjuvant therapy in free radical-based diseases,
mainly neurodegenerative disorders. Indeed, curcumin belongs to the family of hormetins and the
enhancement of the cell stress response, mainly the heme oxygenase-1 system, is actually considered
the common denominator for this dual response. However, evidence-based medicine has clearly
demonstrated the lack of any therapeutic effect of curcumin to contrast the onset or progression
of neurodegeneration and related diseases. Finally, the curcumin safety profile imposes a careful
analysis of the risk/benefit balance prior to proposing chronic supplementation with curcumin.
Keywords: hormesis; vitagenes; antioxidants; heme oxygenase
1. Introduction
In recent decades, the increasing aging population and the consequent rise in chronic degenerative
diseases has led to an augmented investigation of the environmental factors involved in their origin and
progression. There is growing evidence indicating that oxidative stress contributes to the etiology and
the progression of neurodegenerative diseases, such as Alzheimer’s Disease (AD), Parkinson’s Disease
(PD), Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS) [1,2]. From a pathogenetic
viewpoint, neurodegenerative disorders are characterized by the progressive loss of neurons in
different areas of the central nervous system, leading to cognitive, behavioral, sensory, and motor
dysfunctions [3–11]. Common pathological features of neurodegenerative diseases are also oxidative
stress, accumulation of certain aggregated proteins, depletion of endogenous antioxidant enzyme
activity, mitochondrial dysfunction, and neuroinflammation [12]. The link between aging and
neuroinflammation has been referred to as “neuro-inflammaging”, which denotes the modulation of a
multiple array of genes/proteins: activated microglia and astrocytes increase both nuclear factor-κB
(NF-κB) and cyclooxygenase-2 (COX2) and inducible nitric oxide synthase (iNOS) levels; this, in
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turn, induces the release of pro-inflammatory cytokines, such as interleukin-6 (IL-6), interleukin-1β
(IL-1β) and neurotoxic factors, such as reactive oxidative species (ROS) and tumor necrosis factor-α
(TNF-α), leading to neuronal death and subsequent cognitive deficits manifested in neurodegenerative
diseases [13,14]. Increased NF-κB activation, also trough Toll Like Receptors 4 (TLR4) and the Innate
Immune Signal Transduction Adaptor (MYD88), induces release of pro-inflammatory factors, such
as TNF-α, IL-1β, IL-6 and iNOS, with a consequent increase in inflammation-mediated signals in a
vicious cycle promoting and sustaining neuro-inflammaging. Neuroprotective curcumin, by inducing
upregulation of the vitagene system and NF-E2-related factor 2 (Nrf2) and by inhibiting NF-κB activation,
is able to break the vicious cycle and hence, limit the progression of the neurodegenerative diseases.
The heat shock response contributes to maintaining a neuroprotective state against
neuroinflammation [1,15]. This adaptive response, which requires the activation of pro-survival
pathways as well as the production of molecules endowed with anti-oxidant and anti-apoptotic
activities, is reliant upon the control of protective genes known as vitagenes [2,12,16] (Figure 1).
The “vitagene” system includes members of the heat shock protein family, such as heme oxygenase-1
(HO-1), heat shock protein (Hsp70), thioredoxin/thioredoxin reductase (Trx/TrxR), sirtuins (Sirt-1) and
γ-glutamyl cysteine synthetase (γ-GCS) [17–19].
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leads to increased inflammation, and a vicious circle is established that supports neuro-inflammaging. 
The neuroprotective curcumin inducing upregulation of vitagene system and Nrf2 could be able to 
inhibit the NF-κB activation and then break the vicious circle, ending the progression of the 
neurodegenerative disease. 
Currently, chronic supplementation with natural products, derived from plants and herbs, in 
the context of prevention and treatment of neurodegenerative disorders, is considered a new field of 
investigation [20,21] and preclinical studies have suggested that curcumin could alleviate 
neuroinflammatory progression [22–24]. Although curcumin possesses good therapeutic efficacy in 
the treatment of different diseases, supplementation with curcumin is difficult due to its poor oral 
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the treatment of different diseases, supplementation with curcumin is difficult due to its poor oral
bioavailability, low solubility in aqueous solution, and degradation under physiological conditions [25].
In this review, we focus on the evidence leading to the hormetic effects of curcumin, in particular
the interaction with the HO-1 system. In addition, the possible advantages of using novel delivery
systems of curcumin, which possesses a higher stability and an increased bioavailability than free
curcumin, for novel nutraceutical interventions, will be discussed.
2. Curcumin
Curcumin, (1,7-bis(4-hydroxy-3-methoxy phenyl)-1,6-hep-tadiene-3,5-dione) is a polyphenol
compound extracted from the rhizome of Curcuma longa Linn (family Zingiberaceae) and it is commonly
used in the Asian continent, especially in India, as a spice to color and flavor food. It is also used as
cosmetic product, particularly for skin. The curcuminoid complex, found in the rhizome of turmeric
(2.5–6%) contains curcumin (CUR) (CUR-diferuloylmethane ~85%), demethoxycurcumin (DEM ~15%),
bis-demethoxycurcumin (bis-DEM ~5%), and cyclocurcumin [26]. Curcumin is hydrophobic in nature,
so it has poor solubility in water or hydrophilic solutions (Figure 2), while it is highly soluble in organic
solvents including methanol, ethanol, acetone and dimethyl sulfoxide [27]. Interestingly, curcumin is a
natural fluorophore, with its absorption noted in polar solvents ranging from 408 to 540 nm [28,29].
Curcumin is metabolized to form tetrahydrocurcumin (THC) and hexahydrocurcumin (HHC),
together with a small amount of dihydroferulic acid (DHFA) in rats [30]. Dihydrocurcumin (DHC),
DEM, bis-DEM and the reductive metabolites with glucuronic acid and sulfate were also disclosed, and
CUR-glucuronoside, DHC-glucuronoside, THC-glucuronoside and THC were the major metabolites of
curcumin in mice [31,32]. Recent studies have suggested that some of the metabolites of curcumin also
possess important biological activities. For example, THC could relieve sciatic nerve injury in rats [33]
and DHC could prevent the release of glycosaminoglycans induced by antigens in rat basophilic
leukemia cell line (RBL-2H3), which may inhibit allergic diseases [34].
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Preclinical st ies curcumin have put forth several beneficial effects dealing with its
ant-infla matory, antioxidant, antiproliferative, antiatherosclerosis and antimicrobial properties [35–40].
For these reasons, curcumin has been proposed as an adjuvant treatment of several disorders, including
diabetes, biliary disorders, spinal cord injury and neurodegenerative diseases [41–44]. Despite these
claimed properties, the poor intestinal absorption, structural instability, limited blood brain barrier
(BBB) penetration and rapid degradation of curcumin in the body limits the potential as a therapeutic
agent in clinical trials [45]. In addition, an important aspect for the development of curcumin as a
novel “nutraceutical” formulation deals with obtaining an increased bioavailability and physiological
stability and solubility of this compound in animal models and humans [46–48]. Studies have attempted
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to improve bioavailability by altering curcumin’s chemical structure, by conjugating curcumin with
lipids, encapsulating curcumin in a nanoparticle, exosomes, constructing complexes with manganese or
co-treating curcumin with piperine (Pip) to prevent and treat various neurodegenerative diseases [49–53].
3. Curcumin and Brain Targeting
Despite its beneficial effects in vitro, the main obstacle to the medical use of curcumin is its scarce
oral bioavailability with a very low plasmatic concentration equal to 1% [54]. In fact, it belongs to the
Biopharmaceutics Classification System (BCS) class IV [55].
To date, pharmacokinetic studies have shown that many factors influence the bioavailability
of curcumin, including poor water solubility (about 11 ng/mL) [56], chemical instability, limited
absorption, fast metabolism and rapid systemic elimination [57]. After oral administration, most of
the curcumin is eliminated by fecal excretion while a small quantity is absorbed in the small intestine
and is then rapidly converted to water-soluble metabolites in the liver and eliminated by urine [58].
In addition to the aforementioned “bad” pharmacokinetic properties of curcumin, its application in
brain diseases raises another critical issue, namely the poor penetration of curcumin across the BBB [59].
A promising therapeutic strategy is represented by novel drug delivery systems, which enable the
problems related to curcumin bioavailability to be overcome. New formulations have been developed
to achieve this purpose, such as polymeric and lipid nanoparticles, liposomes and cyclodextrins [58].
Recently, preclinical studies have investigated the effectiveness of curcumin nanocarriers in AD
models. The administration of solid lipid nanoparticles loaded with curcumin (SLN-Cur, 50 mg/kg)
induced a recovery in acetylcholinesterase activity and membrane lipids reduced learning impairment
and cognition loss in an aluminum chloride (AlCl3) mouse model of AD [60]. Furthermore, some
authors have explored the role of poly (lactic-co-glicolic acid loaded with curcumin) (PLGA-Cur) in
neurogenesis, demonstrating that these nanocarriers were able to stimulate in vitro differentiation
and proliferation of neural stem cells as well as improve hippocampal neurogenesis, learning, and
memory function in the AD rat model [61]. In another study, glyceryl monooleate nanoparticles
loaded with Pip and curcumin (GMO-NP-Pip/Cur) inhibited α-synuclein aggregation and apoptosis.
When GMO-NP-Pip/Cur were co-administered with rotenone, motor dysfunction was improved in
a PD mouse model [62]. Finally, SLNP-Cur showed neuroprotective effectiveness in a Huntington’s
disease rat model by restoring cell redox homeostasis and reducing motor impairment [51]. A current
fascinating (interesting) strategy is to trigger curcumin release in the central nervous system (CNS) by
the coupling of ligands on the nanoparticle surface, which allows the brain to be targeted rather than
crossing the BBB. In this regard, Huang et al. [63] tested PLGA-Cur nanoparticles conjugated with S1
peptide (an inhibitor of β-amyloid generation) and calreticulin (CRT) (ligand of transferrin receptor) in
both a cellular model of the (BMEC) (brain microvascular endotelial cells) and a transgenic AD mouse
model (APP/PS1dE9). They demonstrated that S1-CRT-NP+Cur can permeate across the BBB and
spread in the mouse brain and at the same time, the administration lessened the cognitive deficits,
increased the number of synapses, reduced astrogliosis and microgliosis, and decreased inflammation
and oxidative stress. Likewise, a neuroprotective effect was exhibited by lactoferin nanoparticles
loaded with curcumin (Lf-NP-Cur) in neuroblastoma cell line (SK-N-SH) exposed to rotenone as a PD
model [64].
Recently, the delivery to brain of small molecules, proteins and nucleic acids was carried out
by exosomes encapsulation [65]. Wang et al. (2019) first demonstrated that exosomes increased
the solubility and bioavailability of curcumin. They then showed that the exosomes deriving from
curcumin-treated cells (Exo-cur), whose surface is grafted with the endothelial intercellular adhesion
molecule 1 (ICAM-1) and the lymphocyte function-associated antigen 1 (LFA-1), enhanced curcumin
passage across the BBB through receptor-mediated transcytosis, thus allowing us to prevent neurons
dying by inhibiting Tau phosphorylation via the AKT/GSK-3β pathway [53].
Another innovative approach is the intranasal route as it represents a valid treatment route to
deliver drugs directly to the brain, bypassing the BBB, which limits the penetration of most of the
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foreign molecules [65]. In addition, this strategy ensures higher drugs bioavailability and therapeutic
efficacy, and less peripheral side effects than oral administration [66,67].
To date, a few studies have tackled the delivery of curcumin to the brain via the direct nose-to-brain
route for the treatment of neurodegenerative diseases [67]. Various intranasal delivery systems
containing curcumin have been investigated, such as nanoemulsion, thermosensitive poloxamer
hydrogel, hyaluronic acid-based lipid nanoemulsion, and microemulsion-based ion sensitive in situ
gelling system [68–70]. Overall, these preclinical findings suggest that the intranasal route could be
an alternative way to deliver drugs to the brain. However, further studies are needed to establish
clinical applications of this treatment strategy. Vittorio Calabrese holds a patent (WO2004/075883A1)
use of curcumin derivatives or CAPE in the manufacture of a medicament for the treatment of
neurodegenerative disorders, and Thomas M. Di Mauro holds two patents (US2008/0076821A1;
US 20090326275A1) for intranasal curcumin formulations based on clinical testing on AD patients [67].
Although many efforts are being made to increase curcumin’s bioavailability in order to lead
to its clinical application, the efficacy, safety and suitability of these drug delivery systems is still to
be clarified.
4. Curcumin and Neuroinflammation
Of particular interest to public health and medicine is the potential of curcumin to affect the nervous
system. Curcumin (100 mg/kg twice a day for 50 days intragastrically) contrasted extrapyramidal
symptoms and increased HO-1 expression through Akt/Nrf2 phosphorylation in the substantia nigra
pars compacta of rats treated with rotenone, a pharmacological tool able to destroy dopaminergic
neurons and therefore, used to induce experimental Parkinson’s disease (PD) [71]. Curcumin displayed
a neuroprotective effect by reducing protein misfolding and aggregation through upregulation of heat
shock proteins such as Hsp90, Hsp70, Hsp60, and Hsp40 in mice models [72]. A recent study reported
a neuroprotective role of curcumin in an SH-SY5Y cell model of PD against toxic injury by regulating
the Hsp90 pathway [73]. Curcumin was also demonstrated to exert a neuroprotective effect in rats who
underwent ischemia/reperfusion injury and this effect has been related to the direct scavenger effect of
curcumin as well as to a curcumin-induced interference with the apoptotic machinery [74]. In addition,
curcumin increased antioxidant molecules GSH and enzymes such as CAT and SOD [75]. It was found
that curcumin alleviated the manifestations of NDs by scavenging ROS, disrupting amyloid plaques,
and exhibiting anti-inflammatory and anti-apoptotic effects [76]. The impact of curcumin on neural
stems cells and other neural cells is quite interesting. Several experimental studies have been published
on the capacity of curcumin to affect neural stem cells. While these studies have used a range of
neural stem cells, i.e., day 15 embryonic cortex from Sprague Dawley rats [77], rodent spinal cord stem
cells [78], SVZ brain region from young Wistar rats [79], C17.2 cells from the cerebellum of neonatal
mice, four days old [80]. All of them displayed hormetic-like biphasic dose responses. While there was
some variation with respect to the optimal dose, the responses of the four models were remarkably
similar. In addition, there was some degree of inter-study variation for the maximum stimulation, with
this ranging from approximately 115% to 190%. The width of the stimulation was also somewhat
variable, ranging from a low being less than 5-fold to about 25-fold. Limited mechanistic follow-up
investigations revealed that curcumin activated the p3 MAP kinase and MEK/pathways [78,80]. It is
important to note that the concentration responses of the neural stem cells were also similar to those
of non-neural stem cells such as reported for human mesenchymal stem cells [81] and mouse 3T3-L1
preadipocytes [82]. The above findings with neural stem cells are highly consistent with the results of
other neuronal biological model experimental systems. These studies include a wide range of non-stem
nerve cell responses, such as the effects of curcumin on copper-induced cell oxidative stress [83], striatal
cell viability [84] and cell proliferation in PC12 cells [85] and Schwmann cells [86]. Curcumin also
protected neurons from beta amyloid [87–91]. In a complementary fashion, Lim et al. (2001) [92]
reported that curcumin was protective against amyloid pathology in an Alzheimer’s transgenic mouse
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models. Likewise, curcumin was found to prevent rotenone- and salsolinol-induced toxicity in a
Parkinson’s disease model [93].
5. Curcumin, Hormesis and Neuroinflammation
The dose response is central to biology, toxicology, medicine and public health. The dose response
often reflects the underlying biology of cells, revealing processes of activation, toxicity and repair.
To be better understood, the dose-response needs to be assessed overtime, since living entities are not
static but respond to various types of information, such as chemical and physical signals, as well as
damage. The dose response, therefore, is dynamic and should be seen as a dose-time-effect process.
This is often seen in the context of adaptive responses. Within such a framework, the dose response
often displays a dynamically changing biphasic dose response that reflects the process of hormesis.
Hormesis is a biphasic dose response that displays a low-dose stimulation and a high-dose
inhibition. It can occur as a result of direct stimulation or as an overcompensation to a disruption in
homeostasis [94,95]. In the case of the overcompensation stimulation type of hormesis, this process
initially displays an inhibition/toxicity reflected in a threshold or linear dose response. However,
the compensatory response, which is usually most effective at lower doses, eventually displays a
biphasic dose response at later time points. Regardless of whether the resulting biphasic dose response
occurs via direct stimulation or via the overcompensation stimulation, the quantitative features are
the same. That is, the low dose stimulation has been shown to be invariably modest, with most of
the maximum stimulatory responses being only about 30–60% greater than the control group. The
fact that the maximum stimulation is consistently shown to be modest and independent of the mode
of stimulation strongly suggests that the hormetic dose response provides a quantitative description
of the limits of biological plasticity. In fact, it has been reported that the quantitatively features of
the hormetic dose response are also independent of mechanism [96]. That is, it is independent of the
receptor and cell signaling pathway, clearly suggesting a very general strategy for biological resource
management in the integration of vast signaling and repair process activities.
The hormetic dose response may be typically observed for highly integrative biological endpoints,
such as a growth, fecundity, tissue repair, memory, longevity and numerous endpoints. All tend to
conform to the quantitative features of the hermetic dose response. The features may also extend
to the field of preconditioning/adaptive responses where the vast majority of observations revealed
a hormetic dose response [97,98]. Other endpoints, such as chemical-induced hair growth, are also
uniformly hermetic. [99] has revealed that the concept of hormesis is extremely generalizable, being
independent of biological model, endpoint point, inducing agent, age or gender, potency of the
inducing agent and mechanism. Therefore, the hormetic dose response has been highly conserved
within an evolutionary framework and has vast biological, biomedical and medical implications.
These implications extend to affect essentially all the pharmacological agents that are designed to
enhance biological performance, such as increasing memory, strengthening bones, reducing damage
from heart attacks and strokes and reducing age-related damage to multiple systems. The fact that
hormesis is central to biology and human adaptive and repair responses makes it a key factor affecting
how pharmaceutical companies study and assess new drugs. For example, essentially all anxiolytic,
anti-seizure and memory-enhancing drugs display hormetic dose responses. This means that the
most that one can expect to improve functionality is only within the 30–60% range. These agents
are constrained to act within the limits of biological plasticity, which is described by the hormetic
dose-response. Therefore, the situation will strongly influence how potential therapeutic agents are
studied, affecting the study design, that is, the number of doses, the dose range, and the sample size.
This situation also applies to the field of phytochemicals and functional foods, which have the potential
to significantly affect biological systems and health outcomes.
A recent report of 99 herbal extracts indicated that most displayed hormetic dose responses
in the assessment of anti-inflammatory endpoints using two immune cell systems. In fact, all the
biphasic dose responses conformed to the well-recognized features of the hormetic dose response [100].
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Amongst the numerous herbal extracts assessed in that study was curcumin, which also displayed a
hormetic-like biphasic dose response features. Despite the fact that curcumin has been widely studied
and used widely in dietary practices, it only has been recently begun to be seen within a general
hormetic framework. The diversity of curcumin-induced hormetic dose response reveals it to be highly
pleiotropic, affecting a widely diverse range of such responses.
Heme Oxygenase as a Pharmacodynamic Paradigm for Curcumin-Related Hormetic Responses
Heme oxygenase is a microsomal enzyme that catalyzes the degradation of heme in a multistep,
energy-requiring system [101,102]. The reaction catalyzed by HO is the α-specific oxidative cleavage
of heme moieties to form equimolar amounts of ferrous iron, carbon monoxide (CO) and biliverdin
(BV); this latter is then reduced by the cytosolic enzyme biliverdin reductase (BVR) into bilirubin
(BR), which is then conjugated with glucuronic acid and excreted [101–103]. Two main isoforms of
HO have been described and called HO-1 and HO-2: HO-1, also referred to as heat shock protein-32,
is the redox-sensitive inducible isoform of the HO family, whereas HO-2, the constitutive isozyme,
is involved in the physiologic turnover of heme and is also considered as an endogenous probe for
gasotransmitters [101,102]. Indeed, HO-1 is up-regulated by several stimuli, including reactive oxygen
and reactive nitrogen species (ROS and RNS, respectively), ischemia-reperfusion, heat shock, LPS,
hemin and several drugs [102,104]. HO-1 induction is one of the earlier cellular responses to tissue
damage and is responsible for the antioxidant and neuroprotective features of its by-products [101,102].
Increasing evidence has suggested that the HO-1 gene is redox-regulated and its promoter contains
the antioxidant responsive element (ARE), similarly to other antioxidant enzymes [105].
The induction of HO-1 is regulated principally by two upstream enhancers, E1 and E2, which
contain multiple stress (or antioxidant) responsive elements (StRE, also called ARE) that also conform
to the sequence of the Maf recognition element (MARE) [106,107]. There is now evidence to suggest
that the heterodimers of Nrf2 and small Maf proteins (i.e., MafK, MafF and MafG) are directly
involved in the induction of HO-1 through these MAREs [106,107]. Under physiological conditions,
the Kelch-like ECH-associated protein 1 (Keap1) binds Nrf2, which undergoes ubiquitination and
degradation through the proteasome; this is a relatively rapid event, the half-life of Nrf2 degradation
being about 3 h [108–111]. Conversely, under pro-oxidant conditions triggering the cell stress response,
Nrf2 is released from Keap1 and migrates into the nucleus, where it binds to conserved ARE/MARE
sequence(s) [111,112]. However, since the MARE can be bound by various heterodimeric basic leucine
zipper (bZip) factors, including Nrf2 and AP-1, this latter being another HO-1 inducer [113], this
implies the need for fine tuning of the HO-1 gene transcription in order to avoid any unnecessary
up-regulation. This problem could be reconciled by the activity of repressors that prevent non-specific
activation. Transcription factor BTB and CNC homology 1 (Bach1) is a transcriptional repressor
endowed with DNA binding activity; Bach1-heme interaction is mediated by evolutionarily conserved
heme regulatory motifs (HRM), including the cysteine-proline dipeptide sequence [107,114]. Therefore,
a reasonable model accounting for the regulation of HO-1 expression by Bach1 and heme is that
HO-1 gene expression is regulated through antagonism between transcription activators and the
repressor Bach1 [107,115]. While under normal physiological conditions, expression of HO-1 is
repressed by the Bach1/Maf complex, increased levels of heme displace Bach1 from the enhancers
and allow activators, e.g., heterodimer of Maf with Nrf2, to promote the transcription of HO-1
gene [107,114,115]. Several lines of evidence have demonstrated the main role played by HO-1 as a
target for the neuroprotective effects of curcumin (for extensive and updated reviews on this field,
see [116,117]), however, the contribution of the HO-1/BVR system to the hormetic nature of curcumin
is worth mentioning. Both the heme degradation activity of HO-1 and the generation of CO and
BR should be considered as hormetic events because they induce neuroprotection or neurotoxicity,
depending on both concentrations and the cellular redox milieu. The heme catabolic activity of HO-1
increases the amount of ferrous iron [Fe(II)] released from the cyclic tetrapyrrole and this reaction
is not harmful per se, but if released in excess and in the presence of ROS, Fe(II) is responsible for
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lipid peroxidation and cell death [118]. Regarding CO, this gasotransmitter has been shown to have
neuroprotective outcomes by inhibiting pro-oxidant enzymes (e.g., NADPH oxidase) or activating
pro-survival pathways [e.g., the protein kinase B (PKB)/Akt and extracellular signal-related kinase
(ERK)/p38 mitogen-activated protein kinase (MAPK)] [102,104,119]. Conversely, CO has been also
shown to blunt the systemic anti-inflammatory response via the inhibition of the hypothalamic release
of adrenocorticotropin hormone-secretagogues and to activate prostaglandin-endoperoxide synthase,
which, in turn, produces pro-inflammatory cytokines [120–123]. Similarly, BR, a strong antioxidant
due to its ability to scavenge both ROS and RNS [124–128] and if produced in excess, impairs brain
functions and is responsible for severe diseases, such as kernicterus [103,129]. By keeping this in mind,
it is possible to support the notion that the over-stimulation of the HO-1/BVR system may be harmful
and some cells find it useful to repress HO-1 to avoid toxicity [130–132].
The strong link between pharmacodynamics and hormetic responses [133,134] lends support
to the dual outcomes reported for curcumin in several diseases [135–137]. For instance, curcumin
(1–4 g/day for 6 months) increased cholesterol plasma levels in Chinese subjects aged ≥50 years; the
mechanism underlying this effect is not known, although the possible interaction of the polyphenol
with cholesterol absorption cannot be excluded [138]. The potential interaction of curcumin with drug
metabolizing enzymes, such as the cytochrome P450 (CYP) isozymes CYP1A2, CYP2A6, CYP2C6,
CYP2C9 and CYP2DS, has been described [117] (see below).
Intriguingly, most of the evidence about the curcumin-HO-1 interaction in the brain describes
neuroprotective features [117], and this accounts for the potential adjuvant role of this polyphenol in
neurodegenerative disorders [134,139,140].
6. Unresolved Issues
Although curcumin is a natural product, this does not imply a lack of safety issues. The toxic
effects of curcumin by its interaction with the drug metabolizing enzymes has been recently addressed
by Mhillaj et al. [108]. Among the drugs whose plasma levels may undergo toxic fluctuations following
curcumin supplementation are clopidogrel, docetaxel, midazolam, nifedepine, norfloxacin and talinolol.
The interaction between curcumin and tamoxifen is quite interesting. This latter is an antagonist to
estrogen receptors (ER) and is used as an adjuvant therapy in women with breast cancer. Tamoxifen is
a pro-drug because the pharmacological effect is due to endoxifen, a metabolite formed through the
activities of cytochrome P-450 (CYP) isoforms. In this regard, the administration of curcumin with or
without piperine has been shown to inhibit CYP2D6 and CYP3A4 activities, thus reducing tamoxifen
antineoplastic effects through the inhibition of endoxifen formation [141]. Furthermore, curcumin
has been shown to be responsible for severe liver diseases: the Italian National Institute of Health
has reported 19 cases of cholestatic epatitis in subjects assuming curcumin alone or plus piperine as
nutritional supplements (www.salute.gov).
These warnings, together with the recommendation by the European Food Scientific Agency (EFSA)
dealing with the lack of any scientific evidence strong enough to justify curcumin supplementation in
people with inflammatory diseases (e.g., osteoarthritis, rheumatoid arthritis, etc.), raise the question of
an unnecessary use of curcumin both in healthy subjects and the elderly [142].
7. Future Perspectives and Conclusions
These findings demonstrate that curcumin affects a broad range of cell types in a manner that
is consistent with the hormetic-biphasic dose response. This is a case of whether the cells are neural
stem, non-neural stem or other cell types. This is also the case with respect to the endpoint measured.
This means that the capacity of curcumin to enhance biological performance is constrained by the
limits of plasticity and does so in a hormetic fashion. While these findings provide strong evidence that
curcumin commonly acts hormetically, the evidence also suggests that there is a limited concentration
range within which the hormetic response occurs. However, the limited concentration range generally
observed were reported, for the most part, within the context of in vitro studies. It is likely that the
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range of optimal concentration may be considerably broaden within a whole animal context, even
more so within a human framework wherein there is considerable inter-individual variation.
With regard to the potential clinical efficacy of curcumin, there are several pre-clinical data in the
literature confirming that curcumin possesses neuroprotective and cognitive-enhancing properties that
may help delay or prevent neurodegenerative diseases. There is significant evidence indicating that
curcumin can act on multiple pathways identified in the pathogenesis of ND, in particular, curcumin
influences AD Aβ aggregation and Aβ clearance, enhancing innate immune systems and reducing
oxidative stress, improving cognition and delaying the onset of AD [143]. Although clinical literature
data does not presently provide full evidence that curcumin is an efficient neuroprotective agent, owing
to conflicting data, however, it is possible that the lack of results on its therapeutic effect is due to
limited bioavailability: Baum et al. [138] demonstrated a therapeutic effect of curcumin (1–4 g/day per
os for 6 months) on memory and other cognitive skills in subjects with AD. Concerning amyotrophic
lateral sclerosis (ALS), recent clinical trials have demonstrated that either curcumin (600 mg/day per os
for 3–6 months) or nanocurcumin (80 mg/day per os for 12 months) have antioxidant effects in ALS
patients vis-à-vis with the lack of any significant effect in terms of improvement of motor function
and other functional measures [144,145]. According to recent evidence using nano-formulation of
Curcumin [146], promising outcomes were unraveled suggesting that nanocurcumin, as an adjuvant
therapy to riluzole, may have improved the probability of survival in a subgroup of ALS patients with
bulbar symptoms [144]. This sustains the conceivable possibility that new therapeutic strategies with
nanocurcumin can open up new horizons for very interesting expected results that can be translated in
the treatment of PD or MS, as shown in animal studies [147–150]. Brain function is influenced by the
endocrine system, especially by thyroid hormones. Since astrocytes metabolize THs to active form,
they play a central role in the endocrine control of neural environment. Oxidative stress is implicated
in both hypo- and hyper-thyroid conditions [151]. Further clinical studies, mainly conducted by
randomized controlled trials, should be performed to determine the role that curcumin-derived novel
delivery systems can play in the prevention and treatment of neuroinflammation.
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